Eptacog alfa (activated)

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Severe Postpartum Haemorrhage

Conditions

Severe Postpartum Haemorrhage

Trial Timeline

Jun 29, 2020 → Jan 13, 2021

NCT ID

NCT04444856

About Eptacog alfa (activated)

Eptacog alfa (activated) is a pre-clinical stage product being developed by Novo Nordisk for Severe Postpartum Haemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT04444856. Target conditions include Severe Postpartum Haemorrhage.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04444856	Pre-clinical	Completed	Jun 29, 2020	Jan 13, 2021	Severe Postpartum Haemorrhage
NCT01876745	Pre-clinical	Completed	Oct 7, 2014	Jun 1, 2017	Congenital Bleeding Disorder
NCT01830712	Pre-clinical	Completed	Apr 1, 2011	Aug 1, 2011	Congenital Bleeding Disorder
NCT00882778	Pre-clinical	Completed	Apr 1, 2009	May 1, 2010	Congenital Bleeding Disorder
NCT00697320	Pre-clinical	Completed	Jun 1, 2008	Dec 1, 2010	Congenital Bleeding Disorder
NCT00703911	Pre-clinical	Completed	Mar 1, 2008	Jul 1, 2010	Congenital Bleeding Disorder
NCT00266006	Phase 2	Completed	Jan 1, 2006	Apr 1, 2007	Acquired Bleeding Disorder
NCT01561924	Phase 1	Completed	Nov 1, 2005	May 1, 2006	Congenital Bleeding Disorder
NCT00127283	Phase 3	Completed	May 1, 2005	Jan 1, 2007	Acquired Bleeding Disorder
NCT00102037	Phase 2	Completed	Jul 1, 2004	Feb 1, 2006	Acquired Bleeding Disorder
NCT01586936	Pre-clinical	Completed	Mar 10, 1999	Mar 9, 2010	Congenital Bleeding Disorder
NCT01579968	Pre-clinical	Completed	Mar 10, 1999	Mar 9, 2010	Congenital Bleeding Disorder
NCT01579955	Pre-clinical	Completed	Mar 10, 1999	Mar 9, 2010	Congenital Bleeding Disorder

Competing Products

20 competing products in Severe Postpartum Haemorrhage

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	52
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
CT-P17 + EU-approved Humira	Celltrion	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Phase 3	77
tacrolimus	Astellas Pharma	Approved	85
enzalutamide	Astellas Pharma	Phase 1	33
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	77
Alefacept	Astellas Pharma	Approved	85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	52
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
Cefiderocol	Shionogi	Approved	85
eritoran tetrasodium + Placebo	Eisai	Phase 3	77
Donepezil HCl	Eisai	Approved	85
Donepezil Hydrochloride (Aricept)	Eisai	Approved	85
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved